The androgen receptor in breast cancer: Learning from the past

Breast Cancer Research and Treatment

Volumn 124, Issue 3, 2010, Pages 619-621

  Higgins, Michaela J ^a   Wolff, Antonio C ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; SELECTIVE ANDROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BONE DISEASE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; GENE EXPRESSION; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; MYOPATHY; NOTE; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78649321904     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0864-5     Document Type: Note

References (17)

1. Hammond EH, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for immunohistochemical testing of estrogen/progesterone receptors in breast cancer. J Clin Oncol (in press)
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
3. M Clarke AS Coates SC Darby, et al. 2008 Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials Lancet 371 29 40 1:STN:280:DC%2BD1c%2FhtFGqtw%3D%3D 10.1016/S0140- 6736(08)60196-8 18177773 (Pubitemid 351173315)
4. CK Osborne MG Yochmowitz WA Knight III, et al. 1980 The value of estrogen and progesterone receptors in the treatment of breast cancer Cancer 46 2884 2888 1:STN:280:DyaL3M%2FovVWjuw%3D%3D 10.1002/1097-0142(19801215)46:12+<2884: :AID-CNCR2820461429>3.0.CO;2-U 7448733
5. Castellano I, Allia E, Accortanzo V et al (2010) Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat. doi: 10.1007/s10549-010-0761-y
6. SN Agoff PE Swanson H Linden, et al. 2003 Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations Am J Clin Pathol 120 725 731 1:CAS:528: DC%2BD3sXpsVOnsL8%3D 10.1309/42F00D0DJD0J5EDT 14608899
7. S Yeh YC Hu PH Wang, et al. 2003 Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor J Exp Med 198 1899 1908 1:CAS:528:DC%2BD3sXpvFaktb8%3D 10.1084/jem.20031233 14676301 (Pubitemid 38032122)
8. W Schippinger P Regitnig N Dandachi, et al. 2006 Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer Virchows Arch 449 24 30 1:CAS:528:DC%2BD28Xmtlais7g%3D 10.1007/s00428-006-0213-6 16628414 (Pubitemid 43988362)
9. F Moinfar M Okcu O Tsybrovskyy, et al. 2003 Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies Cancer 98 703 711 1:CAS:528:DC%2BD3sXntVWgtbc%3D 10.1002/cncr.11532 12910513 (Pubitemid 36959265)
10. V Kuenen-Boumeester TH Van der Kwast CC Claassen, et al. 1996 The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters Eur J Cancer 32A 1560 1565 1:STN:280:DyaK2s%2FmslOksg%3D%3D 10.1016/0959-8049(96)00112-8 8911118 (Pubitemid 26279124)
11. Y Ogawa E Hai K Matsumoto, et al. 2008 Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers Int J Clin Oncol 13 431 435 1:CAS:528:DC%2BD1cXht1OktrzL 10.1007/s10147-008-0770-6 18946753
12. BL Clarke S Khosla 2009 New selective estrogen and androgen receptor modulators Curr Opin Rheumatol 21 374 379 1:CAS:528:DC%2BD1MXms1yjtrw%3D 10.1097/BOR.0b013e32832ca447 19412100
13. MC Cheang SK Chia D Voduc, et al. 2009 Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer J Natl Cancer Inst 101 736 750 1:CAS:528:DC%2BD1MXmtlyit74%3D 10.1093/jnci/djp082 19436038
14. LM McShane DG Altman W Sauerbrei, et al. 2006 Reporting recommendations for tumor marker prognostic studies (REMARK) Breast Cancer Res Treat 100 229 235 10.1007/s10549-006-9242-8 16932852 (Pubitemid 44631925)
15. AA Peters G Buchanan C Ricciardelli, et al. 2009 Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer Cancer Res 69 6131 6140 1:CAS:528:DC%2BD1MXpt1CgtLs%3D 10.1158/0008-5472.CAN-09- 0452 19638585
16. AM Gonzalez-Angulo K Stemke-Hale SL Palla, et al. 2009 Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer Clin Cancer Res 15 2472 2478 1:CAS:528:DC%2BD1MXjvVWks7c%3D 10.1158/1078-0432.CCR- 08-1763 19276248
17. S Sanga BM Broom V Cristini, et al. 2009 Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family BMC Med Genomics 2 59 10.1186/1755-8794-2-59 19747394